Topic Archives: Novartis (NVS)

Please indulge Doc Gumshoe while he presents his musings on what’s going on in general in the health-care arena, and in particular, which new drugs are getting the FDA blessing and why, as well as which ones are getting the short straw.   My impressions and conclusions are in some cases only loosely based on […]

This article was originally published on March 21, 2019 when the “deadline” touted was March 25. We’ve lightly updated our piece below, but much of it (like the ad) is unchanged from March. The latest ad for Green Chip Stocks is a doozy — reminiscent of the many “the world is about to change” ads […]

Today we’ve got a teaser pitch from Marc Lichtenfeld to consider. It’s an ad for his Oxford Income Letter, but the “fountain of youth” pitch makes it sound like a wild ride of a biotech idea… so let’s dig in and see what we can find, shall we? Sometimes it’s best to start with the […]

Every now and then a reader sends in a question about one of the stock ideas teased by dividend.com, which is a service that looks for, you guessed it, dividend paying stocks. Their standard “tease” is that they send around some hints about the latest stock they’ve added to one of their “best” lists, but […]

We’ve seen a long stream of earnings reports and other worthwhile bits of data on Real Money Portfolio stocks since I last wrote to you, including some that actually included some interesting news, so prepare for a lot of quick updates…. Medical Properties Trust (MPW) reported another quarter of ho-hum… pretty much met the forecasts, […]

The article below was originally published on November 27, 2017, when Jeff Brown’s ads promoting the “God Key” started to show up in our inboxes. It has not been updated or revised, but the new versions of the ad from Brown are very similar to the ones we covered in November, including the description of […]

Remember Ernie Tremblay’s pitch about a “tiny South Texas lab” that was about to cure every disease using its revolutionary CD19 Cancer Vaccine technology, and ignite a bidding war following its fantastical release of exciting information on June 23? Well, it’s back. Not the stock, that’s still languishing around where it was before Tremblay got […]

[ed. note: Michael Jorrin, who I dubbed “Doc Gumshoe” years ago, is a longtime medical writer (not a doctor) who writes for us a couple times a month about health issues and trends.  He does not typically write about specific investment opportunities, but has agreed to our trading restrictions… as with all of our authors, […]

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, and his words and opinions are his own. You can find his bio and his past articles on his Stock Gumshoe page.] “The universe (which others call the Library) is composed of an indefinite and […]

[ed note: Michael Jorrin is longtime medical writer who has been sharing his thoughts with our readers as “Doc Gumshoe” for several years (he’s not a doctor, I gave him the name). He generally covers medical and health news and sometimes health promotions and hype, but he rarely opines about investments or specific stocks. All […]

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. All of his past articles and most recent comments are on his Stock Gumshoe page.] Ho ho ho! And Happy Christmas to all […]

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. All of his past articles and most recent comments are on his Stock Gumshoe page.] “Thanks to you I’m much obliged Such a […]

[Ed. Note: Dr. KSS writes about biotech and medicine for the Irregulars. He has agreed to our trading restrictions, chooses his own topics and his thoughts and opinions are his own. His previous columns and recent comments can be found on his Stock Gumshoe page.] “He had never seen her body so abandoned, so unconscious […]

[ed note: Michael Jorrin, who I like call “Doc Gumshoe,” is a longtime medical writer who shares his thoughts with us a couple times a month — his articles are non-financial in nature, his words and opinions are his own, and you can see his bio and his past pieces here. Enjoy!] Indulge me while […]

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. You can see all of his past articles here.] “Who wants honey? As long as there’s some money?” —–“Cherub Rock,” Smashing Pumpkins, Siamese Dream (words and […]

[Ed. Note: Dr. KSS writes for our Irregulars about medicine and biotech stocks. As always, he has agreed our trading restrictions, and his words and opinions are his own. You can find all of his previous articles here. And now, for some dim sum….] Greetings Irregulars, and welcome to Stock Gumshoe’s festive second BioDimSum shindig, a periodic round-up […]

[ed note: Michael Jorrin, who I like to call “Doc Gumshoe”, is a longtime medical writer (not a doctor) who shares his thoughts with us from time to time, generally on non-financial topics in health and medicine (as today, though, he mentions a couple publicly traded companies). His words and opinions are his own.] The […]

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Gumshoe Irregulars. He has agreed to our trading restrictions, he chooses his own topics, and his words and opinions are his own. Enjoy!] OK, admit it….how many of you have seen the campy films of Baltimore director John Waters? The ones starring the […]

[ed note: Dr. KSS is a paid contributor to Stock Gumshoe who writes about biotech stocks for (and discusses them with) the Irregulars. He chooses his own topics, and his words and opinions are his alone. Enjoy!] Greetings fellow Irregulars!  You’ve all been waiting for it….our first-ever annual ceremony in which we look back on […]

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. His words and opinions are his own.] In A History of New York, Washington Irving opens chapter VIII thus: ”In which the author and reader…fall into a very grave and instructive discourse.” This may prove to be a more unleavened column than […]

Comments

  • Avatar

    I owned Novartis (NVS) last year and did ok, but I got hit by a small foreign tax withholding, even in my IRA account. J...

  • Avatar

    Lubris BioPharma - Novartis $NVS - While searching this morning I found this article via Yahoo Finance: "Lubris BioPharm...

  • Dr. KSS MD PhD

    Serelaxin has failed in phase 3 for Novartis $NVS, a major blow to the company and to the field of heart failure managem...

  • Avatar

    Doc, there is another name that Rodman and Renshaw is also bullish on and you have made both positive and negative comme...

  • Avatar

    Novartis (NVS) touting 13 blockbuster's. https://endpts.com/fighting-a-generic-onslaught-novartis-adds-car-t-to-its-gr...

  • Avatar

    Novartis (NVS) in the hunt along with KITE for the first established CAR-T treatment to come to the market.It should be...

  • Avatar

    Novartis (NVS) thus far doing some impressive work with CTLO19 . https://www.novartis.com/news/media-releases/novarti...

  • Avatar

    Novartis (NVS) doing a big time new RD structure. http://endpts.com/novartis-unveils-a-new-global-rd-structure-with-n...

  • Avatar

    $CLCD long. Amgen ($AMGN) and Novartis’ ($NVS) migraine drug erenumab has hit the primary endpoint in a Phase II trial...

  • Avatar

    CRISPR/Cas9 company Intellia getting set for 140 million IPO with a 75 million partnership intact with Regeneron (REGN) ...

  • Dr. KSS MD PhD

    I closed out my position in Novartis $NVS today after several good years. The chart is broken after a sustained bull run...

  • Avatar

    Novartis (NVS) gets FDA approval of its new heart drug. http://www.forbes.com/sites/johnlamattina/2015/07/08/new-heart-...

  • Avatar

    $JUNO GOOD NEWS! Juno Investors Applaud End to Patent Fight -- Market Talk Cancer-drug developer JUNO gets a lif...

  • Avatar

    This Biotech (Aduro) put in for a IPO in March for 86 million and will be highly sought for after this deal with Novarti...

  • Avatar

    Nice interview about Novartis (NVS) drug LCZ696. http://www.medscape.com/viewarticle/838396?src=wnl_edit_specol Doc Ks...

  • Avatar

    Good Evening, greetings felllow boarders. Hard at work, you need a little diversion. By error I ended up buying EPR...

  • Avatar

    Thanks Dr. KSS. A-gain! Will hold off on $PFE, particularly as I keep pondering Novartis $NVS a company that, while valu...

  • Avatar

    Novartis (NVS) Farydak FDA approved for treatment of multiple mylenoma. http://www.fda.gov/NewsEvents/Newsroom/PressA...

  • Dr. KSS, MD PhD

    Some "selected intelligence" relevant for several stocks of interest here: (1) Novartis $NVS. While this is a very la...

  • Dr. KSS, MD PhD

    Glenn: I will have to do a little deeper digging on $IMUC, I am interested in it, but am trying to persuade myself that ...

  • om sharma

    Companies those working on RNA therapeutics, like Fierce Biotech broke the news that the Swiss giant, Novartis (NVS) was...

  • Avatar

    What effects (if any) can we expect from this development? Here are the lead paragraphs from the Novaratis announcement...

  • Avatar

    Does anyone have an opinion on whether LCZ696 has enough potential to seriously move the needle for Novartis (NVS)? The ...

  • This site and Stock Gumshoe publications and authors do not offer individual financial, investment, medical or other advice. Nothing on this site should ever be considered to be personal advice, research or an invitation to buy or sell any securities. We also make mistakes and bad decisions sometimes, and our reasoning or data should be checked against trusted sources before they inform your investing decisions. Choices regarding how to invest your money or otherwise manage your life or finances are yours, we share only our analysis and opinion and all authors or commenters are individually responsible for the words and opinions they share here. Please read our important disclaimers and policies. Stock Gumshoe is supported by subscribers and by sponsors and advertisers. Stock Gumshoe's employee authors will disclose holdings in any stock covered at time of publication and will not trade in any stocks written about for at least three days after publication. Please see below for complete disclosure, disclaimer and policy information.

    Connect with Travis

    website designed by Gravity Switch